AZD-5069
Tier C — Watch / tradeAZD-5069
Targets：CXCR1, CXCR2
Indications (approved)：Head and neck squamous cell carcinoma, Castration-resistant prostate cancer, 胰腺导管癌, Asthma, Chronic obstructive pulmonary disease, Lung disease, 呼吸障碍, Bronchiectasis
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| AZD-5069 | 878385-84-3 | - |
| AZD-5069-001 | 113211-94-2 | 1-(bromomethyl)-2,3-difluorobenzene |
| AZD-5069-002 | 2171459-69-9Available | 6-hydroxy-2-thioxo-2,3-dihydropyrimidin-4(1H)-one |
| AZD-5069-003 | 654073-28-6 | 2-((2,3-difluorobenzyl)thio)pyrimidine-4,6-diol |
| AZD-5069-004 | 654073-29-7 | 4,6-dichloro-2-((2,3-difluorobenzyl)thio)pyrimidine |
| AZD-5069-005 | 74183-62-3 | (R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol |
| AZD-5069-006 | 878385-81-0 | 4-chloro-2-((2,3-difluorobenzyl)thio)-6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)pyrimidine |
| AZD-5069-007 | 654073-32-2 | azetidine-1-sulfonamide |
| AZD-5069-008 | 878385-80-9 | N-(2-((2,3-difluorobenzyl)thio)-6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)pyrimidin-4-yl)azetidine-1-sulfonamide |
| AZD-5069-009 | 50-81-7 | (R)-5-((S)-1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one |
| AZD-5069-010 | 50271-42-6 | (R)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-3,4-dihydroxyfuran-2(5H)-one |
| AZD-5069-011 | 92973-39-2 | (R)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyacetic acid |
| AZD-5069-012 | 92973-40-5 | methyl (R)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyacetate |
| AZD-5069-013 | 166249-17-8 | methyl (R)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(tosyloxy)acetate |
| AZD-5069-014 | 128056-99-5 | (S)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyethyl 4-methylbenzenesulfonate |
| AZD-5069-015 | 128057-03-4 | (S)-2,2-dimethyl-4-((R)-oxiran-2-yl)-1,3-dioxolane |
Frequently asked questions
What are the approved indications of AZD-5069?
Approved indications include: Head and neck squamous cell carcinoma, Castration-resistant prostate cancer, 胰腺导管癌, Asthma, Chronic obstructive pulmonary disease, Lung disease, 呼吸障碍, Bronchiectasis.
When does the AZD-5069 patent expire?
No public expiry year is available for AZD-5069 yet; this page updates once verified.
How many synthesis routes are recorded for AZD-5069?
1 synthesis routes are recorded; the shortest is 12 steps with 45 mg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy AZD-5069 intermediates?
1 intermediate CAS of AZD-5069 are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for AZD-5069 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21